Adalimumab is a single clone antibody that reorganizes the entire human source, IgG1, capable of combining specific properties with the cause of cancer necrosis (TNF)-α and its biological activity, thus playing an important role in the treatment of rheumatism arthritis (RA). The following are some of the main advantages of the Adam alone against the treatment of rheumatism arthritis:
1. Rapid and effective control of inflammation
The single resistance of Adam quickly alleviates arthritis, pain and rigidity. Clinical studies have shown that the high response and disease mitigation rates of Adam monotherapy effectively control the progress of the disease, slow down the destruction of the joints, and improve the functioning of patients ‘ activities and health-related quality of life.
2. Significant improvement in symptoms
A single anti-RA treatment can significantly improve the symptoms of joint pain, swelling and morning rigidity. Studies have shown that the quality of life has improved significantly after 24 weeks of monotherapy using Adam.
3. Defusion of joint damage
A single-mud wood against a joint acacias can effectively improve the cartilage composition of early RA patients and prevent joint damage. In addition, the stand-alone resistance in Adam could significantly slow the progress of radiology for structural joint damage.
4. Improving the quality of life
Patients who use the Adam stand alone show a significant improvement in the health assessment form (HAQ) and in the quality of life rating (SF-36), as well as an improvement in their daily living and working abilities.
Good security and tolerance
The security of the Adam stand alone is good and the incidence of serious adverse incidents is low. The common adverse effects are infections, but the relatively low incidence points to the high overall safety of Adam alone.
6. High rates of drug retention
Data from the RHUMADADA register show that the retention rate of ATM-soldier drugs is significantly better than that of other biological agents, which means that patients are more inclined to use ATM-soldled over the long term.
7. International authoritative guidelines recommended
Based on a rich evidence base, the international authoritative guide recommends TNF inhibitors as a first line of choice after the failure of traditional treatment for RA patients.
8. Flexibility of treatment
The Adam single resistance, which can be used alone or in conjunction with other drugs, such as ammonium butterflies, provides flexibility for treatment. Joint treatment can improve the efficacy of treatment, especially for early RA patients.
9. Improving laboratory indicators
After the single antibiotic treatment, the levels of acute inflammatory reactions (C-reacting protein (CRP), erythrocyte deposition (ESR)) and serocellular factors (IL-6) fell rapidly compared to baseline levels, leading to a reduction in serum levels of matrix metallic protein enzymes (MMP-1 and MMP-3), which have been reshaped and damaged by cartilage.
10. Long-term efficacy maintenance
Based on the results of the extended study, the ACR response can be sustained by the use of ATM alone, in which patients are treated with ATM mono-anti-Achammal (up to 30 months) or monopharmaceutical (up to 5 years).
Based on the above, the anti-Adam alone has a significant place in the treatment of rheumatism arthritis because of its rapid efficacy, significant improvement in symptoms, protection against syndrome, prevention of structural damage, improvement of quality of life and good safety and tolerance. Patients should work closely with doctors to develop individualized treatment programmes.
